HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer
April 28, 2022 08:00 ET
|
HiberCell, Inc.
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutic candidates to address therapeutic resistance, cancer relapse and metastasis,...
HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment
March 03, 2022 08:00 ET
|
HiberCell, Inc.
In-person presentation taking place Wednesday, March 9, in the session beginning at 5:00pm MSTPresentation in Trained Immunity in Disease Treatment Session at Keystone Symposia in Banff, AB,...
HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors
February 24, 2022 08:00 ET
|
HiberCell, Inc.
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, has initiated...
HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Breast Cancer
December 14, 2021 08:00 ET
|
HiberCell
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today...
HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium
December 07, 2021 10:58 ET
|
HiberCell
Open-label phase 2 clinical trial is actively recruiting new patients and opening new sitesResults to be presented in a poster session at SABCS 2021 on December 8, 2021NEW YORK, Dec. 07, 2021 (GLOBE...
HiberCell Appoints Jonathan Lanfear as Chief Operating Officer
September 30, 2021 08:00 ET
|
HiberCell
Expands Board of Directors with Appointment of Cindy Jacobs, PhD, MD NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical stage biotechnology company developing therapeutics to treat...
HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU
September 08, 2021 08:00 ET
|
HiberCell
NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced today that the U.S. Food and...
HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.
August 16, 2021 08:00 ET
|
HiberCell
NEW YORK and BOSTON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced today the...
HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer
June 29, 2021 08:00 ET
|
HiberCell
NEW YORK, June 29, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, today announced the appointment of Mark J....
HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator
June 10, 2021 08:00 ET
|
HiberCell
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today...